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Abdominal aortic aneurysm regression by medical treatment: Possibility or pipe dream?B. Timothy Baxter, MD, Omaha, NebAlthough the magnitude of the problem posed by
abdominal aortic aneurysms (AAA) has long been known
to vascular surgeons, the public is only now becoming
aware of this threat. A number of investigators, primarily
vascular surgeons, have considered, investigated, and writ-
ten about the possibility that AAA expansion might be
inhibited through medical treatment. The cover of the
December 11, 2005, issue of Nature Medicine shows a
micrograph of an aneurysm with the caption “Mending
Aortic Aneurysms.” The photograph (Fig) is from a re-
markable article published in that issue by Yoshimura et al,1
who open the door to the possibility that medical treatment
could lead to aneurysm regression. Dr Robert Thompson, a
vascular surgeon from Washington University, wrote the
invited commentary in that journal.2 This was an exhaustive
study: truly a model for the conduct of research for scien-
tists in any field. Dr Robert Koch, the great German scien-
tists who established the tenets that define the conduct of
quality research, would have been pleased.
Using a variety a state-of-the-art techniques, Yo-
shimura et al1 investigated the proximal cause of the phe-
notypic changes in the smooth muscle cell (SMC) that
Fig. Schematic summarizing the findings of Yoshimura et al.
Products of invading inflammatory cells cause local upregulation of
Jun N-terminal kinase in the smooth muscle cell (SMC). This
results in phenotypic changes in the expression of the SMC that
lead to matrix degradation and aneurysm formation.
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only the excessive production of a family of matrix degrad-
ing enzymes called matrix metalloproteinases (the metal
zinc is integral to their function), or MMPs for short, the
authors identified an intracellular signaling mechanism
with broader implications for the matrix: a switch that not
only turns up matrix-degrading enzymes, but also simulta-
neously shuts down the expression of matrix proteins that
might assist with repair and maintenance of the matrix. This
switch is an intracellular signaling protein known as Jun
N-terminal kinase (JNK). JNK is a member of a family of
kinase proteins called the mitogen-activated protein (MAP)
kinases. These kinases are integral to all basic cell functions,
including proliferation, differentiation, regulation of tran-
scription, and programmed cell death. Much of the work
was performed by using a mouse model of aortic aneurysm
developed by Longo et al3 from our laboratory.
We knew that MMP inhibition could block formation
of a new aneurysm or arrest expansion of an existing aneu-
rysm in animals. Evidence for this concept was first pro-
vided by Petrinec et al4 and presented at the annual meeting
for the Society of Vascular Surgery in 1995. In this work,
experimental aortic aneurysm was inhibited through the
use of a nonspecific inhibitor of MMPs. Most were sur-
prised to learn that this nonspecific inhibitor was doxycy-
cline, a safe and commonly used antibiotic that had become
relatively impotent against common infection because of
bacterial resistance. This interesting and advantageous side
effect was found to be unrelated to the antibiotic properties
of doxycycline. The effectiveness of doxycycline has since
been confirmed in a number of different animal models of
aortic aneurysm.3,5,6 MMP modulation by tetracyclines is
not completely understood but appears to occur at a num-
ber of different levels7 downstream to the JNK switch
identified by Yoshimura.
A more refined hypothesis about aneurysm formation
has been evolving on the basis of studies published over the
past several years. The SMC, the resident cell that maintains
the elastin and collagen matrix in large arteries, has become
the focus of aneurysm pathogenesis. Rather than blaming
an intrinsic structural weakness within the matrix, as had
been done in Marfan syndrome, these studies taught us that
an abnormality in the matrix creates an unhealthy atmo-
sphere that significantly alters SMC behavior.8-11 The SMC
loses its identity and no longer serves its primary function:
maintenance and protection of the matrix. Yoshimura et al1
have identified an alteration in JNK signaling as the primary
cause of this change in the SMC. They then ask and answer
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restored the normal SMC phenotype? Using two different
animal models of AAA, they blocked the intracellular sig-
naling protein, JNK, a protein that is increased in human
AAA tissue, and found complete regression of established
aneurysms. As the aorta returned to normal size, the dam-
aged elastin in the wall also regained its normal lamellar
structure. This repair occurred in association with increased
matrix expression and decreased MMP expression.
At this point, you will rightly begin to wonder whether
this could be achieved in patients with small aneurysms.
The ability of the healthy animal aorta to heal after injury is
clearly different from that of a patient with an AAA. Even in
small (3.5-5.5 cm) aneurysms, the SMC population is
significantly diminished, and many of the SMCs manifest
features consistent with their progression toward senes-
cence.12 Furthermore, the ability of human adult SMCs to
produce significant amounts of elastin is limited. Thus,
seeing the complete repair and regression of an aneurysm in
our patients will likely require restoration of a normal SMC
population: something that might be achieved in the future
through stem cell research.
As we await the scientific and technologic advances that
will be required for reversing aneurysmal disease, our ef-
forts should focus on the present-day potential to identify
and inhibit the continued expansion of small aortic aneu-
rysms. Although other experimental drugs can inhibit
MMPs and AAA formation, doxycycline is presently the
most appealing prospect because it is cheap, readily avail-
able, and safe. Requisite to its consideration for use in a
clinical trial is proof (1) that it would be tolerated by elderly
AAA patients and compatible with their multiple medica-
tions and (2) that its oral administration could inhibit
MMPs in the aneurysm wall. Both of these prerequisites
have been addressed,13,14 and preliminary clinical data
suggest that doxycycline will inhibit aneurysm expansion in
humans.15 The time is right to begin translating the basic
science observations made by vascular surgeons and other
scientists. The next logical step is a prospective, multi-
center, randomized trial of doxycycline in patients with
small AAAs.REFERENCES
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